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OBJECTIVE: This is a health economic evaluation of the long
acting insulin analogue, insulin detemir (IDet) when type 2 dia-
betes patients are switched from either oral antidiabetics (OAD)
or from neutral protamine Hagedorn (NPH) insulin. The data
used as clinical input for the analysis was the Austrian sub-
population of the large observational trial, PREDICTIVE.
METHODS: A published validated diabetes model was used to
estimate the long-term cumulative incidence of complications,
life expectancy (LE), quality-adjusted life expectancy (QALE)
and lifetime costs when switching to IDet from OADs or NPH.
The outcomes were modeled based on the clinical ﬁndings and
validated Austrian costs and treatment patterns. The analysis
used the-third party health care payer perspective. Future costs
and clinical beneﬁts were discounted at 5% per annum.
RESULTS: Conversion to insulin detemir was projected to
improve life expectancy by 0.624 years when switching from
OADs and 0.201 years from NPH. Quality-adjusted life years
(QALYs) increased by 0.52 versus OADs and 0.368 versus NPH.
Direct medical costs over patient lifetimes were projected to be
increased by €5585 compared to OAD-treatment and €2206
versus NPH treatment. Thus, incremental cost-effectiveness
ratios of IDet versus OAD and NPH treatment were €10,739
and €5,996, respectively. Estimates were controlled by multiple
sensitivity analyses and were found to be robust. Probabilistic
sensitivity analyses showed that the cost-effectiveness acceptabil-
ity percentages with a threshold of €30,000 were 100% for
OAD switch and 99.9% for NPH switches. CONCLUSION:
Short-term improvements seen when switching to IDet from
OADs or NPH were projected to show improvements in quality-
adjusted life expectancy with a cost-effectiveness ratio which fell
well within the range usually considered acceptable value for
money.
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OBJECTIVE: A pooled analysis of three clinical trials showed
the therapy beneﬁts of treating type 1 diabetic patients (mean age
40.3 years, duration of diabetes 16.3 years, HbA1c 8.3%, BMI
25.2 kg.m-2) with insulin detemir (IDet) versus neutral protamine
Hagedorn (NPH) insulin as the basal component of basal-bolus
therapy when used in combination with either insulin aspart
(IAsp) or human soluble insulin (HSI). The analysis demon-
strated a short-term improvement for detemir over NPH in
HbA1c (0.13% points lower), a decrease in hypoglycemic events
(by 4%) and lower body mass index (BMI) (0.21 kg.m-2).
METHODS: A published validated diabetes model was used to
estimate the long-term cumulative incidence of complications,
life expectancy (LE), quality-adjusted life expectancy (QALE)
and lifetime costs for IDet versus NPH regimens. Treatment
pattern and costs in the Portuguese setting were taken from
published sources and validated with clinical experts. All out-
comes were discounted at 5% annually. RESULTS: The IDet arm
was associated with an increase in life expectancy, compared to
NPH, of 0.062 years with a resulting gain in QALE of 0.184
quality-adjusted life years, QALYs (SD) (6.3  0.06 versus
6.12  0.06 QALYs) due to a reduction in diabetes-related com-
plications. Increased treatment costs for IDet resulted in greater
total lifetime costs per patient than with NPH (€37,760  743
versus €33,403  738), leading to an incremental cost-
effectiveness ratio of €23,691 per QALY gained. The results were
robust when tested for parameter sensitivity. Cost-effectiveness
acceptability with a threshold of €50,000 is 90%. CONCLU-
SION: Short-term improvements seen with IDet versus NPH in
basal-bolus therapy were projected to show improvements in
quality-adjusted life expectancy with a cost-effectiveness ratio
which fell well within the range usually considered acceptable
value for money.
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OBJECTIVE: To compare medical costs between long term
somatostatin analogs, lanreotide Autogel and octreotide LAR in
the treatment of patients with Acromegaly, from an institutional
perspective. METHODS: Cost-effectiveness analysis using a deci-
sion tree model that simulates the cost and efﬁcacy of the treat-
ment of acromegaly with long term somatostatin analogs, for a
temporary horizon of 15 months was conducted. The effective-
ness measure was the percentage of patients achieving a reduc-
tion in IGF-1 and growth hormone levels, obtained from clinical
trials published in international literature. The average dose used
in the analysis was 96.9 for lanreotide Autogel and 26.4 for
octreotide LAR. Only direct medical costs were considered in the
analysis. Costs were estimated using 2007 prices and are
expressed in United States dollars (exchange rate of 10.93 pesos
per US dollar). RESULTS: The treatment with lanreotide Autogel
showed the best average cost per acromegalic patient treated
with $21,645.60, followed by the treatment with octreotide LAR
with a cost of $24,614.40. Thirty percent of patients achieved a
reduction of IGF-1 and growth hormone to safe levels with both
treatments. Thus, the treatment with lanreotide Autogel had the
lowest cost per successfully treated patient: $72,151.90; followed
by the treatment with octreotide LAR with a cost of $82,047.80.
The univariate and probabilistic sensitivity analysis both showed
that results of the base analysis do not change, provided that the
price ratio of comparators is less than 1.18. CONCLUSION: The
percentage of patients achieving normal IGF-1 and growth levels
is similar for both treatments. Lanreotide Autogel is the treat-
ment associated with a lower drug cost in the Mexican context.
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OBJECTIVES: Premixed and preﬁlled disposable devices are now
available to administer liquid Human Growth Hormone (hGH).
The study objective was to conduct a Cost Minimization Analysis
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